<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01529671</url>
  </required_header>
  <id_info>
    <org_study_id>B3291011</org_study_id>
    <nct_id>NCT01529671</nct_id>
  </id_info>
  <brief_title>A Safety And Tolerability Study Of PF-05089771 In Healthy Subjects And In Subjects With Otseoarthritis Of The Knee</brief_title>
  <official_title>An Investigator And Subject Blinded, Sponsor Open, Randomized, Placebo Controlled, Multiple Dose Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of Pf-05089771 In Healthy Subjects And In Subjects With Osteoarthritis Of The Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is primarily to determine the safety and toleration and&#xD;
      pharmacokinetics of PF-05089771 following escalating multiple doses lasting for 14 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability of PF-05089771</measure>
    <time_frame>Days 1-16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) for PF-05089771 in plasma (measured in ng/mL)</measure>
    <time_frame>Days 1, 4 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax = Time of maximum concentration of PF-05089771 in plasma (hr)</measure>
    <time_frame>Days 1, 6 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCtau= Area under the curve from the time of dosing to the next dose (ng.hr/mL)</measure>
    <time_frame>Days 1, 6 and 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elimination half life (hr) = rate of elimination of PF-05089771 after the final dose</measure>
    <time_frame>day 14 PK samples collected only for 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf = Area under the curve from the time of dosing extrapolated to infinity (ng.hr/mL)</measure>
    <time_frame>Days 14, over 48 hours of PK samples collection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily pain score throughout the treatment period using an 11-point Numeric Rating Scale (NRS).</measure>
    <time_frame>Days 14, every day over 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily time to ascend and descend stairs.</measure>
    <time_frame>Days 14, every day over 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily pain following stair climbing and descending</measure>
    <time_frame>Days 14, every day over 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily time for self paced walk</measure>
    <time_frame>Days 14, every day over 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily pain following self paced walk.</measure>
    <time_frame>Days 14, every day over 24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Experimental intervention: PF-05089771 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetics (PK) of PF-05089771.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Experimental intervention: PF-05089771 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Experimental intervention: PF-05089771 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with osteoarthritis of the knee will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Experimental intervention: PF-05089771 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elderly Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and Pharmacokinetic (PK) of PF-05089771.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Experimental intervention: PF-05089771 or placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive multiple doses of PF-05089771 or placebo twice daily to investigate the safety/tolerability and PK of PF-05089771.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05089771</intervention_name>
    <description>PF-05089771 will be dosed as a suspension twice daily (BID)</description>
    <arm_group_label>Cohort 1: Experimental intervention: PF-05089771 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05089771</intervention_name>
    <description>PF-05089771 will be dosed as a suspension twice daily (BID)</description>
    <arm_group_label>Cohort 2: Experimental intervention: PF-05089771 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05089771</intervention_name>
    <description>PF-05089771 will be dosed as a suspension twice daily (BID)</description>
    <arm_group_label>Cohort 3: Experimental intervention: PF-05089771 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05089771</intervention_name>
    <description>PF-05089771 will be dosed as a suspension twice daily (BID)</description>
    <arm_group_label>Cohort 4: Experimental intervention: PF-05089771 or placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05089771</intervention_name>
    <description>PF-05089771 will be dosed as a suspension BID</description>
    <arm_group_label>Cohort 5: Experimental intervention: PF-05089771 or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects or female subjects of non-child bearing potential between the&#xD;
             ages of 18 and 55 years, inclusive.&#xD;
&#xD;
          -  elderly cohort : healthy male and/or female subjects of 65 and 74 years,&#xD;
&#xD;
          -  cohort 3: subjects with osteoarthritis of the knee: Male or female subjects not of&#xD;
             child bearing potential between the ages of 18 and 75 years inclusive at the time of&#xD;
             entering the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or&#xD;
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,&#xD;
             seasonal allergies at time of dosing).&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, gastrectomy).&#xD;
&#xD;
          -  A positive urine drug screen.&#xD;
&#xD;
          -  History of regular alcohol consumption exceeding 14 drinks/week for females or 21&#xD;
             drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of&#xD;
             beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.&#xD;
&#xD;
          -  Treatment with an investigational drug within 60 days (or as determined by the local&#xD;
             requirement, whichever is longer) or 5 half-lives preceding the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  12-lead ECG demonstrating QTc &gt;450 msec or a QRS interval &gt;120 msec at Screening. If&#xD;
             QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more&#xD;
             times and the average of the three QTc or QRS values should be used to determine the&#xD;
             subject's eligibility.&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs and dietary supplements within 7 days or&#xD;
             5 half-lives (whichever is longer) prior to the first dose of study medication.&#xD;
&#xD;
          -  As an exception, acetaminophen/paracetamol may be used at doses of ≤1 g/day. Limited&#xD;
             use of non-prescription medications that are not believed to affect subject safety or&#xD;
             the overall results of the study may be permitted on a case-by-case basis following&#xD;
             approval by the sponsor.&#xD;
&#xD;
          -  Blood donation of approximately 1 pint (500 mL) or more within 56 days prior to&#xD;
             dosing.&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Unwilling or unable to comply with the Lifestyle guidelines described in this&#xD;
             protocol.&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or&#xD;
             investigational product administration or may interfere with the interpretation of&#xD;
             study results and, in the judgment of the investigator, would make the subject&#xD;
             inappropriate for entry into this study.&#xD;
&#xD;
        for cohort 3: Evidence of relapse or recurrence of clinically significant endocrine,&#xD;
        metabolic, pulmonary, hepatic, osteo-mio-artricular, gastrointestinal, cardiovascular,&#xD;
        renal, , psychiatric or neurological disease, or neurological disease less than 28 days&#xD;
        prior to screening.&#xD;
&#xD;
        Symptomatic OA of the hip ipsilateral to index knee which the patient considers more&#xD;
        painful than the knee. History of diseases other than OA that may involve the index knee in&#xD;
        the last 12 months prior to screening, including but not limited to: inflammatory joint&#xD;
        diseases (i.e rehumatoid arthritis and gout), calcium crystal diseases, bursitis,&#xD;
        tendinitis, tumors and cysts, ligament injuries, bone fractures, post-infective&#xD;
        pathologies; widespread chronic pain conditions (ie, fibromyalgia) and neuropathic&#xD;
        disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>B-1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B3291011&amp;StudyName=A%20Safety%20And%20Tolerability%20Study%20Of%20PF-05089771%20In%20Healthy%20Subjects%20And%20In%20Subjects%20With%20Otseoarthritis%20Of%20The%20Knee</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>February 6, 2012</study_first_submitted>
  <study_first_submitted_qc>February 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2012</study_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

